Skip to content
AnalystLens

Intuitive Surgical 8-K Report, Financial Results (Jul 22, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 22, 2025
Period End
July 22, 2025
Security
ISRG
In the record · 2016–202610-K1110-Q338-K100

ISRG filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Nov ’26Nov ’26

01—Abstract

Summary

Summary of the 8-K filed July 22, 2025. Cited figures are marked; the original filing is the authoritative source.

Intuitive Surgical (ISRG) reported Q2 2025 results that were strong on nearly every headline metric.

Revenue rose 21% year over year to $2.44 billiona, with worldwide da Vinci procedure growth of approximately 17% and Ion procedure volume up roughly 52%. The company placed 395 da Vinci systems (versus 341 a year earlier), including 180 da Vinci 5 systems (versus 70), and the installed base reached 10,488 systems, up 14%. GAAP net income attributable to Intuitive was $658 million ($1.81 per diluted share), and non-GAAP EPS was $2.19 versus $1.78.

GAAP income from operations rose to $743 millionb from $567 million, and the company ended the quarter with $9.53 billion in cash and investments. The key watch item is margin. Management narrowed its 2025 non-GAAP gross margin guidance to 66%-67%, down from 69.1% in 2024, citing an estimated tariff impact of about 1.0% of revenue, and warned that additional or modified tariffs could have a material effect.

Management also guided to worldwide da Vinci procedure growth of 15.5%-17% and non-GAAP operating expense growth of 10%-14%. Investors should note that Q2 GAAP net income was flattered by a large excess tax benefit from share-based compensation ($33 millionc, or $0.09 per share), and that Q1 GAAP net income benefited from an unusually large $145 million excess tax benefit. Quarterly comparisons are therefore noisier than the top-line trend suggests.

Overall, the quarter shows robust demand, accelerating da Vinci 5 adoption, and continued expansion of the installed base, with the principal risks centered on tariff-driven gross margin pressure and macroeconomic or regulatory developments. The company also announced EU MDR certification for da Vinci 5 (excluding force feedback) and Japanese clearance for da Vinci 5 across most specialties. This 8-K furnishes the earnings press release under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.

02—Key points

Key Highlights

  1. Revenue grew 21% year over year to $2.44 billion, driven by da Vinci procedure growth of about 17% and higher system placements.
  2. da Vinci 5 placements reached 180 in Q2 2025, up from 70 a year earlier, while total system placements rose to 395 from 341 and the installed base grew 14% to 10,488 systems.
  3. Ion procedure volume grew about 52% and instruments and accessories revenue rose 18% to $1.47 billion.
  4. GAAP EPS was $1.81 (vs. $1.46) and non-GAAP EPS was $2.19 (vs. $1.78); GAAP income from operations rose to $743 million from $567 million.
  5. 2025 non-GAAP gross margin guidance was lowered to 66%-67% from 69.1% in 2024, including an estimated 1.0% of revenue tariff impact.
  6. 2025 guidance calls for da Vinci procedure growth of 15.5%-17% and non-GAAP operating expense growth of 10%-14%.
  7. Cash, equivalents, and investments reached $9.53 billion, up $431 million in the quarter, and EU MDR certification and Japanese clearance were obtained for da Vinci 5.

03—Questions

Frequently Asked Questions

  1. Why did Intuitive's gross margin guidance decline for 2025?

    Management lowered its non-GAAP gross profit margin expectation to 66%-67% of revenue, compared with 69.1% in 2024. The company attributes this mainly to an estimated tariff impact of about 1.0% of revenue, and it warned that additional or modified tariffs could have a material effect on results.

  2. How strong was demand for da Vinci systems and procedures in Q2 2025?

    Demand was robust. Worldwide da Vinci procedures grew about 17%, system placements rose to 395 from 341, and da Vinci 5 placements more than doubled to 180 from 70. The installed base grew 14% to 10,488 systems.

  3. Is GAAP net income a clean read on the quarter's performance?

    Not entirely. GAAP net income included a $33 million excess tax benefit from share-based compensation ($0.09 per diluted share), and Q1 2025 included a much larger benefit of $145 million. Non-GAAP results exclude these items, and the company also excludes share-based compensation, amortization, and litigation charges, which are recurring costs investors should weigh carefully.

  4. What is the outlook for procedure growth and operating expenses in 2025?

    Intuitive expects worldwide da Vinci procedure growth of approximately 15.5%-17% in 2025, compared with 17% in 2024. It expects non-GAAP operating expense growth of 10%-14%, compared with 10% in 2024.

  5. What regulatory milestones were announced with the results?

    In July 2025, Intuitive obtained EU MDR certification for da Vinci 5 for adult and pediatric use in abdominopelvic and thoracoscopic procedures, excluding force feedback, which it intends to pursue later. In June 2025, it received Japanese clearance for da Vinci 5 across most surgical specialties, excluding cardiac indications.

04—Continue

← View all 8-K filings